Vertex Pharmaceuticals Incorporated
521.12USD
-7.7800 (-1.47%)
Computing valuation metrics…
Valuation
P/E (TTM)
29.98x
P/E (Forward)
25.76x
EV/EBITDA
25.64x
EV/Revenue
10.18x
P/S (TTM)
10.49x
P/B
6.52x
FCF Yield
2.87%
Dividend Yield
0.00%
Gross Margin
86.00%
Operating Margin
37.95%
Net Margin
35.00%
Peer Comparison — Biotechnology
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| VRTXVertex Pharmaceuticals Incorporated | $132.08B | 29.98x | 25.64x | 2.87% | 12.45% | 0.00% |
| REGNRegeneron Pharmaceuticals, Inc. | $83.43B | 20.06x | 16.08x | 3.67% | 16.70% | 0.45% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $62.33B |
| 38.24x |
| 968.98x |
| 1.22% |
| 59.30% |
| — |
| MRNAModerna, Inc. | $54.14B | — | — | 0.55% | 2.10% | — |
| RPRXRoyalty Pharma plc | $35.01B | 32.58x | 24.44x | -3.41% | 16.50% | 1.47% |
| ROIVRoivant Sciences Ltd. | $30.20B | — | — | -3.73% | -33.50% | — |
| INCYIncyte Corporation | $25.22B | 15.85x | 10.67x | 4.68% | 37.70% | — |
| BNTXBioNTech SE | $24.65B | — | — | -1.01% | -59.50% | — |
| ASNDAscendis Pharma A/S | $17.11B | 20.08x | 63.64x | 0.07% | 114.70% | — |